Seattle, WA, United States of America

Conor J MacEvilly


Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 51(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Unveiling the Innovation of Conor J MacEvilly: Pioneering Mucosal Delivery of Y2 Receptor-Binding Peptides

Introduction: Conor J MacEvilly, a brilliant inventor based in Seattle, WA, has made significant strides in the realm of pharmaceutical compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides. With three patents under his belt, Conor is a trailblazer in the field of treating and preventing obesity through innovative medical solutions.

Latest Patents: Conor's recent patents revolve around "Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity." These patents describe pharmaceutical compositions that incorporate Y2 receptor-binding peptides, such as peptide YY (PYY), Neuropeptide Y (NPY), or Pancreatic Peptide (PP), along with mucosal delivery-enhancing agents. By focusing on enhanced nasal mucosal delivery of peptide YY, Conor's inventions offer new avenues for treating a variety of diseases and conditions in mammalian subjects, particularly obesity.

Career Highlights: Conor J MacEvilly has been a pivotal figure at Nastech Pharmaceutical Company, Inc., where his groundbreaking research and innovative approaches have propelled the company's efforts in developing cutting-edge pharmaceutical solutions. His expertise in drug delivery mechanisms has garnered widespread recognition in the scientific community.

Collaborations: Alongside esteemed colleagues such as Steven C Quay and Gordon Brandt, Conor has fostered a collaborative environment at Nastech Pharmaceutical Company, Inc., where innovative ideas flourish, leading to the successful implementation of novel drug delivery systems.

Conclusion: In conclusion, Conor J MacEvilly's inventive spirit and dedication to advancing pharmaceutical science have redefined the landscape of mucosal delivery of Y2 receptor-binding peptides. His contributions not only hold immense promise for treating obesity but also underscore the transformative power of innovation in the realm of medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…